APA (7th ed.) Citation

CK, K., TP, R., K, K., S, S., NH, H., A, N. A., . . . RJ, A. (2026). Uttroside B, a US FDA-designated 'Orphan Drug', mitigates the development of hepatocellular carcinoma and its pulmonary metastasis via EGFR/ERK-mediated inhibition of SREBP-1 and STAT-3. Cell death discovery, 12(1), . https://doi.org/10.1038/s41420-026-03055-5

Chicago Style (17th ed.) Citation

CK, Keerthana, et al. "Uttroside B, a US FDA-designated 'Orphan Drug', Mitigates the Development of Hepatocellular Carcinoma and Its Pulmonary Metastasis via EGFR/ERK-mediated Inhibition of SREBP-1 and STAT-3." Cell Death Discovery 12, no. 1 (2026). https://doi.org/10.1038/s41420-026-03055-5.

MLA (9th ed.) Citation

CK, Keerthana, et al. "Uttroside B, a US FDA-designated 'Orphan Drug', Mitigates the Development of Hepatocellular Carcinoma and Its Pulmonary Metastasis via EGFR/ERK-mediated Inhibition of SREBP-1 and STAT-3." Cell Death Discovery, vol. 12, no. 1, 2026, https://doi.org/10.1038/s41420-026-03055-5.